Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07737275 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Screening With Portable X-rays for Rapid Recognition of TB

Study acronym: SPOT-TB
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Completion pushed from Mar 10, 2028 to May 25, 2028 · Study sites: 0 to 1 · Primary completion date: May 14, 2027 to May 25, 2027 · 2 more Show 5 more changesShow less
    • Completion pushed from Mar 10, 2028 to May 25, 2028
    • Study sites: 0 to 1
    • Primary completion date: May 14, 2027 to May 25, 2027
    • Start date changed from estimate of Aug 15, 2026 to Aug 25, 2026
    • Eligibility criteria expanded, about 8 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SPOT-TB (Screening with Portable X-rays for rapid recOgniTion of TB) is a prospective study evaluating a community-based tuberculosis (TB) screening strategy for migrant populations in New York City. The screening intervention integrates mobile ultra-portable digital chest radiography with artificial intelligence-assisted image interpretation, tuberculosis symptom assessment, latent tuberculosis infection testing, and HIV testing. Participants with concerning screening findings are referred for appropriate clinical evaluation. The study will evaluate the feasibility, acceptability, and effectiveness of this integrated screening strategy for improving early identification of active pulmonary tuberculosis and linkage to care in community settings.
Trial Details
NCT Number NCT07737275
Lead Sponsor Columbia University
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Tuberculosis (TB), Tuberculosis Infection, Latent, HIV (Human Immunodeficiency Virus)
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov